| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
|
J Nucl Med
|
2003
|
3.26
|
|
2
|
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
|
Clin Cancer Res
|
2006
|
2.71
|
|
3
|
Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner.
|
Phys Med Biol
|
2007
|
2.48
|
|
4
|
Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study.
|
Biol Psychiatry
|
2008
|
2.28
|
|
5
|
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
|
J Clin Oncol
|
2011
|
2.10
|
|
6
|
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters.
|
Eur J Nucl Med Mol Imaging
|
2006
|
2.08
|
|
7
|
Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum.
|
Neuropsychopharmacology
|
2008
|
1.88
|
|
8
|
Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies.
|
J Nucl Med
|
2009
|
1.88
|
|
9
|
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.
|
J Nucl Med
|
2012
|
1.78
|
|
10
|
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.
|
J Nucl Med
|
2009
|
1.77
|
|
11
|
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
|
J Nucl Med
|
2009
|
1.68
|
|
12
|
Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET.
|
J Cereb Blood Flow Metab
|
2006
|
1.68
|
|
13
|
Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.63
|
|
14
|
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability.
|
Acta Oncol
|
2013
|
1.62
|
|
15
|
Hyperaemic microvascular resistance is not increased in viable myocardium after chronic myocardial infarction.
|
Eur Heart J
|
2007
|
1.60
|
|
16
|
Partial volume corrected image derived input functions for dynamic PET brain studies: methodology and validation for [11C]flumazenil.
|
Neuroimage
|
2007
|
1.56
|
|
17
|
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
|
J Nucl Med
|
2003
|
1.56
|
|
18
|
Comparison of HRRT and HR+ scanners for quantitative (R)-[11C]verapamil, [11C]raclopride and [11C]flumazenil brain studies.
|
Mol Imaging Biol
|
2015
|
1.52
|
|
19
|
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.
|
Radiology
|
2011
|
1.48
|
|
20
|
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
|
J Nucl Med
|
2010
|
1.47
|
|
21
|
Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
|
Eur J Cancer
|
2005
|
1.46
|
|
22
|
Postinjection transmission scanning in myocardial 18F-FDG PET studies using both filtered backprojection and iterative reconstruction.
|
J Nucl Med
|
2004
|
1.42
|
|
23
|
Measurement of left ventricular volumes and function with O-15-labeled carbon monoxide gated positron emission tomography: comparison with magnetic resonance imaging.
|
J Nucl Cardiol
|
2005
|
1.41
|
|
24
|
Partial volume correction strategies for quantitative FDG PET in oncology.
|
Eur J Nucl Med Mol Imaging
|
2010
|
1.40
|
|
25
|
Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.
|
Eur J Nucl Med Mol Imaging
|
2013
|
1.40
|
|
26
|
Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28.
|
PLoS One
|
2011
|
1.31
|
|
27
|
Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function.
|
Neuroimage
|
2010
|
1.31
|
|
28
|
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
|
Cancer Biother Radiopharm
|
2003
|
1.31
|
|
29
|
Impact of [¹⁸F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.28
|
|
30
|
Image-derived input functions for PET brain studies.
|
Eur J Nucl Med Mol Imaging
|
2008
|
1.26
|
|
31
|
Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment.
|
J Nucl Med
|
2011
|
1.24
|
|
32
|
Simplified parametric methods for [11C]PIB studies.
|
Neuroimage
|
2008
|
1.23
|
|
33
|
Quantifying heterogeneity in human tumours using MRI and PET.
|
Eur J Cancer
|
2012
|
1.20
|
|
34
|
Image derived input functions for dynamic High Resolution Research Tomograph PET brain studies.
|
Neuroimage
|
2008
|
1.20
|
|
35
|
Comparison of 3D-OP-OSEM and 3D-FBP reconstruction algorithms for High-Resolution Research Tomograph studies: effects of randoms estimation methods.
|
Phys Med Biol
|
2008
|
1.19
|
|
36
|
Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion.
|
J Cereb Blood Flow Metab
|
2009
|
1.19
|
|
37
|
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.
|
Eur J Nucl Med Mol Imaging
|
2008
|
1.17
|
|
38
|
Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology.
|
EJNMMI Res
|
2012
|
1.15
|
|
39
|
Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.
|
Eur J Nucl Med Mol Imaging
|
2009
|
1.15
|
|
40
|
Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET.
|
J Nucl Med
|
2009
|
1.14
|
|
41
|
18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study.
|
J Nucl Med
|
2010
|
1.13
|
|
42
|
In vivo validation of reconstruction-based resolution recovery for human brain studies.
|
J Cereb Blood Flow Metab
|
2009
|
1.12
|
|
43
|
Optimized dose regimen for whole-body FDG-PET imaging.
|
EJNMMI Res
|
2013
|
1.12
|
|
44
|
Evaluation of reference tissue models for the analysis of [11C](R)-PK11195 studies.
|
J Cereb Blood Flow Metab
|
2006
|
1.11
|
|
45
|
Reply to: Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity.
|
Eur J Nucl Med Mol Imaging
|
2013
|
1.11
|
|
46
|
Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study.
|
Arthritis Res Ther
|
2012
|
1.11
|
|
47
|
Development of a tracer kinetic plasma input model for (R)-[11C]PK11195 brain studies.
|
J Cereb Blood Flow Metab
|
2005
|
1.11
|
|
48
|
Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany.
|
Mol Imaging Biol
|
2013
|
1.10
|
|
49
|
Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies.
|
J Cereb Blood Flow Metab
|
2012
|
1.10
|
|
50
|
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
|
Eur J Nucl Med Mol Imaging
|
2012
|
1.10
|
|
51
|
HRRT versus HR+ human brain PET studies: an interscanner test-retest study.
|
J Nucl Med
|
2009
|
1.09
|
|
52
|
Optimization algorithms and weighting factors for analysis of dynamic PET studies.
|
Phys Med Biol
|
2006
|
1.09
|
|
53
|
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
|
J Nucl Med
|
2011
|
1.08
|
|
54
|
Multicenter harmonization of 89Zr PET/CT performance.
|
J Nucl Med
|
2013
|
1.07
|
|
55
|
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy.
|
Am J Physiol Heart Circ Physiol
|
2007
|
1.07
|
|
56
|
Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography.
|
Arthritis Rheum
|
2008
|
1.04
|
|
57
|
Amygdala activity in obsessive-compulsive disorder with contamination fear: a study with oxygen-15 water positron emission tomography.
|
Psychiatry Res
|
2004
|
1.04
|
|
58
|
Accuracy of 3-dimensional reconstruction algorithms for the high-resolution research tomograph.
|
J Nucl Med
|
2008
|
1.04
|
|
59
|
Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia.
|
Neurology
|
2012
|
1.02
|
|
60
|
Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
|
Brain
|
2012
|
1.02
|
|
61
|
Measurement of metabolic tumor volume: static versus dynamic FDG scans.
|
EJNMMI Res
|
2011
|
1.02
|
|
62
|
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
|
Eur J Nucl Med Mol Imaging
|
2012
|
1.02
|
|
63
|
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.01
|
|
64
|
Microglial activation in healthy aging.
|
Neurobiol Aging
|
2010
|
1.01
|
|
65
|
Comparison of plasma input and reference tissue models for analysing [(11)C]flumazenil studies.
|
J Cereb Blood Flow Metab
|
2007
|
1.01
|
|
66
|
Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment.
|
J Cereb Blood Flow Metab
|
2007
|
1.01
|
|
67
|
Standardization of quantitative imaging: the time is right, and 18F-FDG PET/CT is a good place to start.
|
J Nucl Med
|
2011
|
1.00
|
|
68
|
Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy.
|
J Nucl Med
|
2004
|
0.99
|
|
69
|
Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy.
|
IEEE Trans Med Imaging
|
2012
|
0.99
|
|
70
|
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
|
Eur J Nucl Med Mol Imaging
|
2004
|
0.98
|
|
71
|
18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.
|
J Cancer Res Clin Oncol
|
2007
|
0.97
|
|
72
|
Off-line motion correction methods for multi-frame PET data.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.96
|
|
73
|
Day-to-day test-retest variability of CBF, CMRO2, and OEF measurements using dynamic 15O PET studies.
|
Mol Imaging Biol
|
2011
|
0.96
|
|
74
|
Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder.
|
Eur Neuropsychopharmacol
|
2013
|
0.96
|
|
75
|
Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study.
|
Radiology
|
2006
|
0.95
|
|
76
|
Evaluation of methods for generating parametric (R-[11C]PK11195 binding images.
|
J Cereb Blood Flow Metab
|
2007
|
0.95
|
|
77
|
Microglial activation in Alzheimer's disease: an (R)-[¹¹C]PK11195 positron emission tomography study.
|
Neurobiol Aging
|
2012
|
0.95
|
|
78
|
Longitudinal amyloid imaging using 11C-PiB: methodologic considerations.
|
J Nucl Med
|
2013
|
0.95
|
|
79
|
Measurement of 18F-FDG concentrations in blood samples: comparison of direct calibration and standard solution methods.
|
J Nucl Med Technol
|
2003
|
0.95
|
|
80
|
Quantitative comparison of analytic and iterative reconstruction methods in 2- and 3-dimensional dynamic cardiac 18F-FDG PET.
|
J Nucl Med
|
2004
|
0.95
|
|
81
|
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
|
J Nucl Med
|
2009
|
0.93
|
|
82
|
Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.93
|
|
83
|
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
|
Ann Surg
|
2011
|
0.93
|
|
84
|
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
|
Clin Nucl Med
|
2012
|
0.92
|
|
85
|
Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies.
|
Phys Med Biol
|
2007
|
0.91
|
|
86
|
Quantification of subendocardial and subepicardial blood flow using 15O-labeled water and PET: experimental validation.
|
J Nucl Med
|
2006
|
0.91
|
|
87
|
Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies.
|
Mol Imaging Biol
|
2009
|
0.90
|
|
88
|
Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results.
|
Eur J Nucl Med Mol Imaging
|
2009
|
0.90
|
|
89
|
Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury.
|
J Nucl Med
|
2011
|
0.89
|
|
90
|
Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study.
|
Radiology
|
2014
|
0.88
|
|
91
|
Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany.
|
Mol Imaging Biol
|
2014
|
0.88
|
|
92
|
Test-retest variability of various quantitative measures to characterize tracer uptake and/or tracer uptake heterogeneity in metastasized liver for patients with colorectal carcinoma.
|
Mol Imaging Biol
|
2014
|
0.87
|
|
93
|
Reproducibility of tumor perfusion measurements using 15O-labeled water and PET.
|
J Nucl Med
|
2008
|
0.87
|
|
94
|
Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography.
|
J Cereb Blood Flow Metab
|
2006
|
0.87
|
|
95
|
Increased cerebral (R)-[(11)C]PK11195 uptake and glutamate release in a rat model of traumatic brain injury: a longitudinal pilot study.
|
J Neuroinflammation
|
2011
|
0.87
|
|
96
|
Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
|
Int J Hyperthermia
|
2006
|
0.87
|
|
97
|
Microvascular function in viable myocardium after chronic infarction does not influence fractional flow reserve measurements.
|
J Nucl Med
|
2007
|
0.86
|
|
98
|
The perfusable tissue index: a marker of myocardial viability.
|
J Nucl Cardiol
|
2003
|
0.86
|
|
99
|
Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments.
|
Leuk Lymphoma
|
2009
|
0.86
|
|
100
|
Effects of rigid and non-rigid image registration on test-retest variability of quantitative [18F]FDG PET/CT studies.
|
EJNMMI Res
|
2012
|
0.86
|
|
101
|
Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?
|
Eur Radiol
|
2015
|
0.86
|
|
102
|
P-glycoprotein function at the blood-brain barrier: effects of age and gender.
|
Mol Imaging Biol
|
2012
|
0.85
|
|
103
|
Reproducibility of quantitative (R)-[11C]verapamil studies.
|
EJNMMI Res
|
2012
|
0.85
|
|
104
|
In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.85
|
|
105
|
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.85
|
|
106
|
SPM analysis of parametric (R)-[11C]PK11195 binding images: plasma input versus reference tissue parametric methods.
|
Neuroimage
|
2007
|
0.85
|
|
107
|
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography.
|
Mol Imaging Biol
|
2006
|
0.85
|
|
108
|
Validation of a multiwell gamma-counter for measuring high-pressure liquid chromatography metabolite profiles.
|
J Nucl Med Technol
|
2004
|
0.84
|
|
109
|
Effects of attenuation correction and reconstruction method on PET activation studies.
|
Neuroimage
|
2003
|
0.83
|
|
110
|
Amyloid and its association with default network integrity in Alzheimer's disease.
|
Hum Brain Mapp
|
2012
|
0.83
|
|
111
|
Hemodynamic changes in ipsi- and contralateral cerebral arterial territories after carotid endarterectomy using positron emission tomography.
|
Surg Neurol
|
2008
|
0.82
|
|
112
|
Reference tissue models and blood-brain barrier disruption: lessons from (R)-[11C]PK11195 in traumatic brain injury.
|
J Nucl Med
|
2009
|
0.82
|
|
113
|
Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer.
|
EJNMMI Res
|
2014
|
0.82
|
|
114
|
Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.
|
PLoS One
|
2012
|
0.82
|
|
115
|
Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET.
|
J Nucl Med
|
2005
|
0.82
|
|
116
|
Initial experience with a prototype dual-crystal (LSO/NaI) dual-head coincidence camera in oncology.
|
Eur J Nucl Med Mol Imaging
|
2004
|
0.82
|
|
117
|
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
|
PLoS One
|
2013
|
0.82
|
|
118
|
Limbic and motor circuits involved in symmetry behavior in Tourette's syndrome.
|
CNS Spectr
|
2012
|
0.81
|
|
119
|
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).
|
BMC Med Phys
|
2008
|
0.81
|
|
120
|
Influence of ROI definition, partial volume correction and SUV normalization on SUV-survival correlation in oesophageal cancer.
|
Nucl Med Commun
|
2010
|
0.80
|
|
121
|
Impact of scar on water-perfusable tissue index in chronic ischemic heart disease: Evaluation with PET and contrast-enhanced MRI.
|
Mol Imaging Biol
|
2006
|
0.80
|
|
122
|
Two decades at the cross-roads of biology, physics and epidemiology: lessons learned in [18F-]FDG positron emission tomography in oncology.
|
Eur J Cancer
|
2010
|
0.80
|
|
123
|
Image derived input functions: effects of motion on tracer kinetic analyses.
|
Mol Imaging Biol
|
2011
|
0.80
|
|
124
|
Bias reduction for low-statistics PET: maximum likelihood reconstruction with a modified Poisson distribution.
|
IEEE Trans Med Imaging
|
2014
|
0.80
|
|
125
|
Simplified parametric methods for [18F]FDDNP studies.
|
Neuroimage
|
2009
|
0.80
|
|
126
|
Matching PET and CT scans of the head and neck area: development of method and validation.
|
Med Phys
|
2002
|
0.79
|
|
127
|
Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.
|
Mol Imaging Biol
|
2014
|
0.79
|
|
128
|
The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.78
|
|
129
|
Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study): A Diagnostic Study Protocol.
|
Neurosurgery
|
2016
|
0.78
|
|
130
|
Optimisation and harmonisation: two sides of the same coin?
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.78
|
|
131
|
Gap filling strategies for 3-D-FBP reconstructions of High-Resolution Research Tomograph scans.
|
IEEE Trans Med Imaging
|
2008
|
0.78
|
|
132
|
No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds.
|
J Cereb Blood Flow Metab
|
2012
|
0.77
|
|
133
|
First evaluation of [11C]R116301 as an in vivo tracer of NK1 receptors in man.
|
Mol Imaging Biol
|
2009
|
0.77
|
|
134
|
Comparison of oxygen-15 PET and transcranial Doppler CO2-reactivity measurements in identifying haemodynamic compromise in patients with symptomatic occlusion of the internal carotid artery.
|
EJNMMI Res
|
2012
|
0.77
|
|
135
|
18 F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma.
|
EJNMMI Res
|
2014
|
0.75
|
|
136
|
Intervention versus standard medical treatment in patients with symptomatic occlusion of the internal carotid artery: a randomised oxygen-15 PET study.
|
EJNMMI Res
|
2013
|
0.75
|
|
137
|
Quantification of the neurokinin 1 receptor ligand [¹¹C]R116301.
|
Nucl Med Commun
|
2011
|
0.75
|
|
138
|
Prediction of functional recovery after revascularization in patients with chronic ischemic myocardial dysfunction: perfusable tissue index by positron emission tomography and contrast-enhanced MRI comparison study.
|
Nucl Med Commun
|
2011
|
0.75
|
|
139
|
Accuracy of 3D acquisition mode for myocardial FDG PET studies using a BGO-based scanner.
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.75
|
|
140
|
Incorporating HYPR de-noising within iterative PET reconstruction (HYPR-OSEM).
|
Phys Med Biol
|
2017
|
0.75
|
|
141
|
Attenuation correction of PET activation studies in the presence of task-related motion.
|
Neuroimage
|
2003
|
0.75
|
|
142
|
Experimental evaluation of iterative reconstruction versus filtered back projection for 3D [15O]water PET activation studies using statistical parametric mapping analysis.
|
Neuroimage
|
2003
|
0.75
|
|
143
|
Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment.
|
Clin Nucl Med
|
2017
|
0.75
|
|
144
|
Myocardial oxygen extraction fraction measured using bolus inhalation of 15O-oxygen gas and dynamic PET.
|
J Nucl Med
|
2010
|
0.75
|
|
145
|
Parametric Method Performance for Dynamic 3'-Deoxy-3'-(18)F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.
|
J Nucl Med
|
2016
|
0.75
|
|
146
|
Parametric [11C]flumazenil images.
|
Nucl Med Commun
|
2012
|
0.75
|
|
147
|
Impact of wavelet based denoising of [11C](R)-PK11195 time activity curves on accuracy and precision of kinetic analysis.
|
Med Phys
|
2008
|
0.75
|